BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soema PC, van Riet E, Kersten G, Amorij JP. Development of cross-protective influenza a vaccines based on cellular responses. Front Immunol 2015;6:237. [PMID: 26029218 DOI: 10.3389/fimmu.2015.00237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Liu Y, Wang Y, Wu Y, Jia P, Shan J, Wu J, Ma G, Su Z. The potential adjuvanticity of quaternized chitosan hydrogel based microparticles for porcine reproductive and respiratory syndrome virus inactivated vaccine. International Immunopharmacology 2016;39:84-91. [DOI: 10.1016/j.intimp.2016.07.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
2 Kumar A, Singh S. Editorial: Influenza Virus Vaccines and Immunotherapies. Front Immunol 2015;6:599. [PMID: 26635813 DOI: 10.3389/fimmu.2015.00599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Zhang Y, Xu C, Zhang H, Liu GD, Xue C, Cao Y. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus. Viruses 2019;11:E405. [PMID: 31052339 DOI: 10.3390/v11050405] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
4 Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines 2016;15:967-76. [PMID: 26954563 DOI: 10.1586/14760584.2016.1164046] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
5 Rekstin A, Isakova-Sivak I, Petukhova G, Korenkov D, Losev I, Smolonogina T, Tretiak T, Donina S, Shcherbik S, Bousse T, Rudenko L. Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein. Biomed Res Int 2017;2017:9359276. [PMID: 28210631 DOI: 10.1155/2017/9359276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lee J, Li Y, Li Y, Cino-Ozuna AG, Duff M, Lang Y, Ma J, Sunwoo S, Richt JA, Ma W. Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge. Vaccine 2021;39:1943-50. [PMID: 33715905 DOI: 10.1016/j.vaccine.2021.02.077] [Reference Citation Analysis]
7 Démoulins T, Ruggli N, Gerber M, Thomann-Harwood LJ, Ebensen T, Schulze K, Guzmán CA, McCullough KC. Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs. Front Immunol 2020;11:622385. [PMID: 33584723 DOI: 10.3389/fimmu.2020.622385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ryu JI, Park SA, Wui SR, Ko A, Han JE, Choi JA, Song MK, Kim KS, Cho YJ, Lee NG. A De-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in Mice. Biomed Res Int 2016;2016:3713656. [PMID: 27891512 DOI: 10.1155/2016/3713656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Soema PC, Rosendahl Huber SK, Willems GJ, Jacobi R, Hendriks M, Soethout E, Jiskoot W, de Jonge J, van Beek J, Kersten GFA, Amorij JP. Whole-Inactivated Influenza Virus Is a Potent Adjuvant for Influenza Peptides Containing CD8+ T Cell Epitopes. Front Immunol 2018;9:525. [PMID: 29593747 DOI: 10.3389/fimmu.2018.00525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Qi M, Zhang XE, Sun X, Zhang X, Yao Y, Liu S, Chen Z, Li W, Zhang Z, Chen J, Cui Z. Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection. Small 2018;14:e1703207. [PMID: 29430819 DOI: 10.1002/smll.201703207] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
11 Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Hum Vaccin Immunother 2018;14:571-8. [PMID: 28933664 DOI: 10.1080/21645515.2017.1377376] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
12 Oyarzún P, Kobe B. Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production. Hum Vaccin Immunother 2016;12:763-7. [PMID: 26430814 DOI: 10.1080/21645515.2015.1094595] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
13 Rowell J, Lo CY, Price GE, Misplon JA, Epstein SL, Garcia M. Conventional influenza vaccines influence the performance of a universal influenza vaccine in mice. Vaccine 2018;36:1008-15. [PMID: 29249542 DOI: 10.1016/j.vaccine.2017.11.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
14 Savic M, Dembinski JL, Kim Y, Tunheim G, Cox RJ, Oftung F, Peters B, Mjaaland S. Epitope specific T-cell responses against influenza A in a healthy population. Immunology 2016;147:165-77. [PMID: 26489873 DOI: 10.1111/imm.12548] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
15 Rajão DS, Pérez DR. Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture. Front Microbiol 2018;9:123. [PMID: 29467737 DOI: 10.3389/fmicb.2018.00123] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 17.0] [Reference Citation Analysis]
16 Kim H, Jang M, Kim Y, Choi J, Jeon J, Kim J, Hwang Y, Kang JS, Lee WJ. Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection. Journal of Pharmacy and Pharmacology 2016;68:406-20. [DOI: 10.1111/jphp.12529] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
17 Lee TY, Kim CU, Bae EH, Seo SH, Jeong DG, Yoon SW, Chang KT, Kim YS, Kim SH, Kim DJ. Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model. Vaccine 2017;35:586-95. [PMID: 28024958 DOI: 10.1016/j.vaccine.2016.12.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
18 Melhem NM. Norovirus vaccines: Correlates of protection, challenges and limitations. Hum Vaccin Immunother 2016;12:1653-69. [PMID: 26836766 DOI: 10.1080/21645515.2015.1125054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Joshi LR, Knudsen D, Piñeyro P, Dhakal S, Renukaradhya GJ, Diel DG. Protective Efficacy of an Orf Virus-Vector Encoding the Hemagglutinin and the Nucleoprotein of Influenza A Virus in Swine. Front Immunol 2021;12:747574. [PMID: 34804030 DOI: 10.3389/fimmu.2021.747574] [Reference Citation Analysis]
20 Dong W, Bhide Y, Marsman S, Holtrop M, Meijerhof T, de Vries-idema J, de Haan A, Huckriede A. Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine. Biotechnol J 2018;13:1700645. [DOI: 10.1002/biot.201700645] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Virk RK, Gunalan V, Tambyah PA. Influenza infection in human host: challenges in making a better influenza vaccine. Expert Rev Anti Infect Ther 2016;14:365-75. [PMID: 26885890 DOI: 10.1586/14787210.2016.1155450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
22 Soema PC, Willems G, Jiskoot W, Amorij J, Kersten GF. Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach. European Journal of Pharmaceutics and Biopharmaceutics 2015;94:427-35. [DOI: 10.1016/j.ejpb.2015.06.026] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
23 Talker SC, Stadler M, Koinig HC, Mair KH, Rodríguez-Gómez IM, Graage R, Zell R, Dürrwald R, Starick E, Harder T, Weissenböck H, Lamp B, Hammer SE, Ladinig A, Saalmüller A, Gerner W. Influenza A Virus Infection in Pigs Attracts Multifunctional and Cross-Reactive T Cells to the Lung. J Virol 2016;90:9364-82. [PMID: 27512056 DOI: 10.1128/JVI.01211-16] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
24 Qiao Y, Jin S, Nie J, Chang Y, Wang B, Guan S, Li Q, Shi Y, Kong W, Shan Y. Hemagglutinin-based DNA vaccines containing trimeric self-assembling nanoparticles confer protection against influenza. J Leukoc Biol 2022. [PMID: 35040188 DOI: 10.1002/JLB.6A1021-535R] [Reference Citation Analysis]
25 Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Hum Vaccin Immunother 2021;:1-14. [PMID: 34582315 DOI: 10.1080/21645515.2021.1977057] [Reference Citation Analysis]
26 Sell S, McKinstry KK, Strutt TM. Mouse Models Reveal Role of T-Cytotoxic and T-Reg Cells in Immune Response to Influenza: Implications for Vaccine Design. Viruses 2019;11:E52. [PMID: 30641955 DOI: 10.3390/v11010052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Lohia N, Baranwal M. Highly conserved hemagglutinin peptides of H1N1 influenza virus elicit immune response. 3 Biotech 2018;8:492. [PMID: 30498665 DOI: 10.1007/s13205-018-1509-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm 2015;94:251-63. [PMID: 26047796 DOI: 10.1016/j.ejpb.2015.05.023] [Cited by in Crossref: 174] [Cited by in F6Publishing: 145] [Article Influence: 24.9] [Reference Citation Analysis]
29 Herrera-Rodriguez J, Meijerhof T, Niesters HG, Stjernholm G, Hovden AO, Sørensen B, Ökvist M, Sommerfelt MA, Huckriede A. A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model. Virology 2018;515:21-8. [PMID: 29223787 DOI: 10.1016/j.virol.2017.11.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
30 Nizolenko LP, Bachinsky AG, Bazhan SI. Evaluation of Influenza Vaccination Efficacy: A Universal Epidemic Model. Biomed Res Int 2016;2016:5952890. [PMID: 27668256 DOI: 10.1155/2016/5952890] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Chen F, Seong Seo H, Ji HJ, Yang E, Choi JA, Yang JS, Song M, Han SH, Lim S, Lim JH, Ahn KB. Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine. Hum Vaccin Immunother 2021;17:485-96. [PMID: 32643515 DOI: 10.1080/21645515.2020.1780091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]